Naz Rahman
Stock Analyst at Maxim Group
(0.28)
# 4,108
Out of 4,873 analysts
37
Total ratings
15.62%
Success rate
-43.61%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.81 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $7.72 | +120.21% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $9 → $5 | $0.80 | +524.61% | 2 | Mar 20, 2025 | |
| SCPH scPharmaceuticals | Maintains: Buy | $20 → $12 | $3.97 | +202.27% | 3 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $27.09 | +158.40% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $2.20 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.13 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.73 | +1,002.38% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.29 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.63 | +375.13% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $9.10 | +1,438.46% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $445.82 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.26 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $2.15 | +132.56% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.88 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.32 | +158.62% | 1 | Feb 25, 2022 |
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.81
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $7.72
Upside: +120.21%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $9 → $5
Current: $0.80
Upside: +524.61%
scPharmaceuticals
Mar 20, 2025
Maintains: Buy
Price Target: $20 → $12
Current: $3.97
Upside: +202.27%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $27.09
Upside: +158.40%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.20
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.13
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.73
Upside: +1,002.38%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.29
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.63
Upside: +375.13%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $9.10
Upside: +1,438.46%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $445.82
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.26
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $2.15
Upside: +132.56%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $0.88
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.32
Upside: +158.62%